AEON Biopharma (NASDAQ:AEON) Trading Up 5% – Here’s Why

AEON Biopharma, Inc. (NASDAQ:AEON)’s share price rose 5% during mid-day trading on Tuesday . The stock traded as high as $0.6981 and last traded at $0.6921. Approximately 23,811 shares were traded during trading, a decline of 80% from the average session volume of 117,744 shares. The stock had previously closed at $0.6592.

Wall Street Analyst Weigh In

Separately, Zacks Research raised AEON Biopharma to a “hold” rating in a report on Wednesday, May 27th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy”.

AEON Biopharma Stock Performance

The stock has a market capitalization of $17.51 million, a price-to-earnings ratio of 3.85 and a beta of 0.61. The business has a 50-day moving average of $0.83 and a 200-day moving average of $0.98.

Institutional Investors Weigh In On AEON Biopharma

A hedge fund recently raised its position in AEON Biopharma stock. XTX Topco Ltd boosted its position in AEON Biopharma, Inc. (NASDAQ:AEON) by 251.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 56,852 shares of the company’s stock after purchasing an additional 40,690 shares during the period. XTX Topco Ltd owned about 0.48% of AEON Biopharma worth $63,000 as of its most recent SEC filing. 22.78% of the stock is currently owned by institutional investors and hedge funds.

About AEON Biopharma

AEON Biopharma, Inc, formerly Allied Energy Corp., is a clinical‐stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. The company applies enzyme replacement and gene therapy platforms to address unmet medical needs in central nervous system and metabolic disorders. Its lead program, AES-103, is being developed as an enzyme replacement therapy for Crigler-Najjar syndrome, a hereditary condition characterized by high levels of unconjugated bilirubin.

Beyond AES-103, AEON Biopharma is advancing AES-201 for X-linked adrenoleukodystrophy (X-ALD), a progressive neurological disorder, and AES-104 for post–COVID-19 conditions, commonly referred to as “long COVID.” These programs are in preclinical or early clinical stages, with ongoing efforts to optimize delivery, evaluate safety profiles and establish proof of concept.